Basic & Clinical Medicine ›› 2010, Vol. 30 ›› Issue (1): 54-58.

• 研究论文 • Previous Articles     Next Articles

Effect of phosphorylated-p38MAPK on caspase-3 expression in substantia nigra of the MPTP mouse model of Parkinson's disease

Zi-feng WEI, Yong-sheng WANG, Qian WANG, Li-ren MA, Zuo-feng ZHANG, Yu-xin ZHANG   

  1. North China Coal Medical College North China Coal Medical College
  • Received:2009-02-17 Revised:2009-05-07 Online:2010-01-05 Published:2010-01-05
  • Contact: Yu-xin ZHANG

Abstract: Objective: To investegate the effect of phosphorylated-P38MAPK(mitogen-activated protein kinase) on the expression of caspase-3 in the substania nigra(SN)of MPTP-induced mouse model of(PD). Methords: Mice were randomly divided into MPTP model group, which were treated with MPTP(30 mg/kg, dissolved in saline, intraperitoneal injection), inhibitor group, which were treated with SB203580(10 mg/kg, dissolved in 5 mg/ml DMSO, intraperitoneal injection) 1 h before injection of MPTP. Once a day for 5 days; control group were treated with saline and DMSO as much as the model group received per day for 5 days. The behavioral were observed, immunohistochemistry and western blot for TH, caspase-3 and phosphorylation of P38MAPK were used to observe the change of positive cell number numbers and the expression level in the SN of midbrain. Results: Compared with the mice in control group, the model group showed typical symtoms of PD with decreased numbers of TH-positive neurons and the protein level of TH in SN of the midbrain by about 60% and 65% respectively(P<0.01), the numbers of caspase-3 and phosphorylation of P38MAPK immunoreactive cells and their protein level in the SN of the midbrain increased markedly(P<0.01). After giving SB203580, the above changes were reduced obviously(P<0.01). Conclusions: In the mouse model of subacute Parkinson's disease induced by MPTP, phosphorylated-P38MAPK regulated caspase-3 in the SN of midbrain, the specific P38MAPK inhibitor SB203580 is neuroprotective to the mouse model.